Evidence map›Paper›PMID 38268545›Full record

ArticleRSC advances2024

Performance and biocompatibility of OSTEMER 322 in cell-based microfluidic applications.

Petr Aubrecht, Jiří Smejkal, Petr Panuška, Klára Španbauerová, Viktorie Neubertová, Pavel Kaule, Jindřich Matoušek, Stanislav Vinopal, Michaela Liegertová, Marcel Štofik and 1 more

Abstract read
In one paragraph

Article in RSC advances, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Petr AubrechtCentre for Nanomaterials and Biotechnology, Faculty of Science, Jan Evangelista Purkyně University in Ústí nad Labem Pasteurova 3632/15 400 96 Ústí nad Labem Czech Republic petr.aubrecht@ujep.cz malyjalga@seznam.cz.ORCID https://orcid.org/0000-0003-0837-1669
Jiří SmejkalCentre for Nanomaterials and Biotechnology, Faculty of Science, Jan Evangelista Purkyně University in Ústí nad Labem Pasteurova 3632/15 400 96 Ústí nad Labem Czech Republic petr.aubrecht@ujep.cz malyjalga@seznam.cz.ORCID https://orcid.org/0000-0003-3180-2703
Petr PanuškaCentre for Nanomaterials and Biotechnology, Faculty of Science, Jan Evangelista Purkyně University in Ústí nad Labem Pasteurova 3632/15 400 96 Ústí nad Labem Czech Republic petr.aubrecht@ujep.cz malyjalga@seznam.cz.ORCID https://orcid.org/0009-0006-8236-6357
Klára ŠpanbauerováCentre for Nanomaterials and Biotechnology, Faculty of Science, Jan Evangelista Purkyně University in Ústí nad Labem Pasteurova 3632/15 400 96 Ústí nad Labem Czech Republic petr.aubrecht@ujep.cz malyjalga@seznam.cz.
Viktorie NeubertováCentre for Nanomaterials and Biotechnology, Faculty of Science, Jan Evangelista Purkyně University in Ústí nad Labem Pasteurova 3632/15 400 96 Ústí nad Labem Czech Republic petr.aubrecht@ujep.cz malyjalga@seznam.cz.ORCID https://orcid.org/0000-0002-3340-0778
Pavel KauleCentre for Nanomaterials and Biotechnology, Faculty of Science, Jan Evangelista Purkyně University in Ústí nad Labem Pasteurova 3632/15 400 96 Ústí nad Labem Czech Republic petr.aubrecht@ujep.cz malyjalga@seznam.cz.ORCID https://orcid.org/0000-0002-2041-4919
Jindřich MatoušekDepartment of Physics, Faculty of Science, Jan Evangelista Purkyně University in Ústí nad Labem Pasteurova 3632/15 400 96 Ústí nad Labem Czech Republic.
Stanislav VinopalCentre for Nanomaterials and Biotechnology, Faculty of Science, Jan Evangelista Purkyně University in Ústí nad Labem Pasteurova 3632/15 400 96 Ústí nad Labem Czech Republic petr.aubrecht@ujep.cz malyjalga@seznam.cz.ORCID https://orcid.org/0000-0001-9352-4580
Michaela LiegertováCentre for Nanomaterials and Biotechnology, Faculty of Science, Jan Evangelista Purkyně University in Ústí nad Labem Pasteurova 3632/15 400 96 Ústí nad Labem Czech Republic petr.aubrecht@ujep.cz malyjalga@seznam.cz.ORCID https://orcid.org/0000-0003-3858-856X
Marcel ŠtofikCentre for Nanomaterials and Biotechnology, Faculty of Science, Jan Evangelista Purkyně University in Ústí nad Labem Pasteurova 3632/15 400 96 Ústí nad Labem Czech Republic petr.aubrecht@ujep.cz malyjalga@seznam.cz.ORCID https://orcid.org/0000-0003-3903-6054
Jan MalýCentre for Nanomaterials and Biotechnology, Faculty of Science, Jan Evangelista Purkyně University in Ústí nad Labem Pasteurova 3632/15 400 96 Ústí nad Labem Czech Republic petr.aubrecht@ujep.cz malyjalga@seznam.cz.ORCID https://orcid.org/0000-0002-7022-2157

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The Off-Stoichiometry Thiol-ene and Epoxy (OSTE+) polymer technology has been increasingly utilised in the field of microfluidics and lab-on-a-chip applications. However, the impact of OSTEMER polymers, specifically the OSTEMER 322 formulation, on cell viability has remained limited. In this work, we thoroughly explored the biocompatibility of this commercial OSTEMER formulation, along with various surface modifications, through a broad range of cell types, from fibroblasts to epithelial cells. We employed cell viability and confluence assays to evaluate the performance of the material and its modified variants in cell culturing. The properties of the pristine and modified OSTEMER were also investigated using surface characterization methods including contact angle, zeta potential, and X-ray photoelectron spectroscopy. Mass spectrometry analysis confirmed the absence of leaching constituents from OSTEMER, indicating its safety for cell-based applications. Our findings demonstrated that cell viability on OSTEMER surfaces is sufficient for typical cell culture experiments, suggesting OSTEMER 322 is a suitable material for a variety of cell-based assays in microfluidic devices.

Identifiers

PMID38268545
PMCPMC10804231

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.